SEARCH

SEARCH BY CITATION

References

  • 1
    Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am J Heart 1991; 121: 124463.
  • 2
    McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA 1993; 270: 220712.
  • 3
    American Heart Association. Heart Disease and Stroke Statistics – 2006 Update. Dallas, TX: American Heart Association.
  • 4
    Michaud CM, McKenna MT, Begg S et al. The burden of disease and injury in the United States 1996. Popul Health Metr 2006; 4: 11.
  • 5
    Thom T, Haase N, Rosamond W et al. Heart disease and stroke statistics – 2006 update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. 2006; 113: e85151, Epub 11 January 2006.
  • 6
    Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995; 346: 164753.
  • 7
    Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual BP to vascular mortality. Lancet 2002; 360: 190313.
  • 8
    Baigent C, Keech A, Kearney PM et al. the Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 126778.
  • 9
    Cushman WC, Basile J. Achieving blood pressure goals: why aren't we? J Clin Hypertens (Greenwich) 2006; 8: 86572.
  • 10
    World Health Organization (WHO). Adherence to Long Term Therapies: Evidence for Action. Geneva: WHO, 2003.
  • 11
    Halpern MT, Khan ZM, Schmier JK et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006; 47: 103948.
  • 12
    Schedlbauer A, Schroeder K, Peters TJ et al. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2004; CD004371.
  • 13
    Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004; CD004804.
  • 14
    Berger ML, Bingefors K, Hedblom EC et al. (eds). Healthcare Cost, Quality and Outcomes: ISPOR Book of Terms. Lawrenceville, NJ: ISPOR, 2003.
  • 15
    ISPOR Medication Compliance and Persistence Special Interest Group (MCP): Accomplishments. International Society for Pharmacoeconomics & Outcomes Research (ISPOR). http://www.ispor.org/sigs/mcp_accomplishments.asp#definition (accessed June 2007).
  • 16
    Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50: 10516.
  • 17
    Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165: 114752.
  • 18
    Larsen J, Vaccheri A, Andersen M et al. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy. Br J Clin Pharmacol 2000; 49: 46371.
  • 19
    Wetzels GE, Nelemans P, Schouten JS et al. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22: 184955.
  • 20
    Sturkenboom MCJM, Picelli G, Dieleman JP et al. Patient adherence and persistence with antihypertensive therapy: one-versus two-pill combinations. J Hypertens 2005; 23 (Suppl. 2): S236.
  • 21
    Choo PW, Rand CS, Inui TS, Lee ML, Ma CC, Platt R. A pharmacodynamic assessment of the impact of antihypertensive non-adherence on blood pressure control. Pharmacoepidemiol Drug Saf 2000; 9: 55763.
  • 22
    Bertholet N, Favrat B, Fallab-Stubi CL, Brunner HR, Burnier M. Why objective monitoring of compliance is important in the management of hypertension. J Clin Hypertens (Greenwich) 2000; 2: 25862.
  • 23
    Blonde L, Wogen J, Kreilick C et al. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003; 5: 42431.
  • 24
    Hope CJ, Wu J, Tu W, Young J, Murray MD. Association of medication adherence, knowledge, and skills with emergency department visits by adults 50 years or older with congestive heart failure. Am J Health Syst Pharm 2004; 61: 20439.
  • 25
    Rosen MI, Rigsby MO, Salahi JT et al. Electronic monitoring and counseling to improve medication adherence. Behav Res Ther 2004; 42: 40922.
  • 26
    Charpentier G, Fleury F, Dubroca I. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. Diabetes Metab 2005; 31: 18995.
  • 27
    Muhlestein JB, Horne BD, Bair TL et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001; 87: 25761.
  • 28
    Howell N, Trotter R, Mottram DR et al. Compliance with statins in primary care. Pharm J 2004; 272: 236.
  • 29
    Simpson SH, Eurich DT, Majumdar SR et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15, Epub 21 June 2006.
  • 30
    Bramley TJ, Gerbino PP, Nightengale BS et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006; 12: 23945.
  • 31
    Breekveldt-Postma NS, Siiskonen SJ, Penning-Van Beest FJA et al. Non-persistent use of antihypertensive drugs leads to increased risk of hospitalizations for acute myocardial infarction or stroke. Abstract presented at: ISPOR; October, 2006. Value Health Suppl 2006; 9: A339.
  • 32
    Sokol MC, McGuigan KA, Verbrugge RR et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 52130.
  • 33
    Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care 2005; 11: S1706.